CCL2 and chronic kidney disease: It was shown that ARNi treatment suppressed the activation of NF-κB factor, inhibiting the activation of its downstream molecules, such as monocyte chemoattractant protein 1 (MCP-1) and NADP oxidase-4, preventing CKD-related cardiovascular dysfunction.